^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TSC-204-C0702

    i
    Other names: TSC-204-C0702, TSC-204-C7, TSC204, TSC 204, TSC-204, TSC-204-C07
    Associations

    News

    Trials
    Company:
    TSCan Therap
    Drug class:
    TCR modulator, MAGE-A1 modulator
    Related drugs:
    Associations

    News

    Trials
    18d
    TSCAN-002: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=840, Active, not recruiting, TScan Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Pan tumor
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702
    8ms
    TSCAN-002: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=840, Recruiting, TScan Therapeutics, Inc. | N=100 --> 840
    Enrollment change
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702
    almost2years
    A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, TScan Therapeutics, Inc. | Initiation date: Nov 2023 --> Feb 2024
    Trial initiation date • IO biomarker • Pan tumor • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    HLA-A*02
    |
    T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702
    2years
    A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, TScan Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Pan tumor • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    HLA-A*02
    |
    T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702
    over2years
    A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, TScan Therapeutics, Inc.
    New P1 trial • Pan tumor • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    HLA-A*02
    |
    T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702